SCHEMBL5160868

SCHEMBL5160868

CCNC(=O)CC(=O)c1ccoc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.50
CYP3A4 P08684 1/20 0.49
PTK2 Q05397 1/20 0.40
ITGAV P06756 2/20 0.38
ADORA2A P29274 2/20 0.37
ADORA1 P30542 2/20 0.37
ADORA3 P0DMS8 1/20 0.37
ADORA2B P29275 1/20 0.37
ITGA2 P17301 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA7 P36544 1/20 0.36
CHRNA4 P43681 1/20 0.36
KCNK3 O14649 1/20 0.36
KCNK9 Q9NPC2 1/20 0.36
HDAC3 O15379 2/20 0.35
HDAC1 Q13547 2/20 0.35
MAPT P10636 1/20 0.35
HDAC4 P56524 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7100741 0.82 TRPA1 (0.53) TRPA1CYP3A4PTK2ITGAVADORA2A
SCHEMBL3273821 0.80 PTK2 (0.50) TRPA1CYP3A4PTK2ITGAVITGA2
SCHEMBL10811976 0.78 TRPA1 (0.56) TRPA1CYP3A4PTK2ITGAVADORA2A
SCHEMBL6627157 0.77
SCHEMBL4995985 0.76 TRPA1 (0.53) TRPA1CYP3A4PTK2ITGAVCHRNB2
SCHEMBL4459301 0.75 TRPA1 (0.53) TRPA1CYP3A4PTK2ITGAVKCNK3
SCHEMBL1642808 0.75 KMT2A (0.49) TRPA1CYP3A4PTK2ADORA2BMAPT
SCHEMBL5158082 0.75 TRPA1 (0.49) TRPA1CYP3A4PTK2ITGAVKCNK3
SCHEMBL5160772 0.74 CYP3A4 (0.54) TRPA1CYP3A4PTK2ITGAVCHRNB2
SCHEMBL826915 0.74 TRPA1 (0.66) TRPA1CYP3A4PTK2ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO TRPA1 4224/4885CYP3A4 7/4885PTK2 2010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.